Possible fifth case of brain infection linked to Tysabri

Share this article:
A possible fifth case of a rare and deadly brain infection linked to the multiple sclerosis (MS) drug Tysabri has been reported to federal regulators, The Wall Street Journal reported today.
The case was reported May 16 through the FDA's Adverse Event Reporting System, which collects reports of possible drug reactions from doctors and drug makers.
An FDA spokeswoman told the newspaper that these reports don't represent confirmed cases.
The fifth possible case was reported by an unnamed health professional and concerns a female patient whose age is undisclosed. No other details of her condition were available, the newspaper report said.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies